Literature DB >> 27385671

Long-lasting extreme anemia during the therapy of acute lymphoblastic leukemia in a Jehovah's Witness patient.

Krzysztof Chojnowski1, Agnieszka Janus2, Katarzyna Bliźniewska2, Marta Robak1, Jacek Treliński3.   

Abstract

BACKGROUND: The treatment of patients with acute leukemia, who due to their religious beliefs refuse to accept blood transfusion, is a great challenge for hematologists. CASE REPORT: We present a case of acute pre-T-lymphoblastic leukemia in a Jehovah's Witness who did not accept blood transfusion during chemotherapy. Standard induction and consolidation chemotherapy was used (according to the PALG ALL-6 regiment).
RESULTS: During consolidation cycles, darbepoietin alfa, intravenous iron, and total parenteral nutrition was administered. Extreme (Hb < 5 g/dL), long-lasting (41 days) anemia was observed with the lowest Hb concentration amounting to 1.3 g/dL (lasting 7 days).
CONCLUSION: We believe this to be the lowest Hb value observed, particularly one that persisted for such a long period of time and resulted in the patient surviving without consequences. The patient remains in complete remission for more than 2 years after diagnosis.
© 2016 AABB.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27385671     DOI: 10.1111/trf.13703

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

Review 1.  Shifting ground and gaps in transfusion support of patients with hematological malignancies.

Authors:  Christine Cserti-Gazdewich
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Surviving Extreme Anaemia.

Authors:  Joana M Esteves; Joana Fernandes; Pedro Oliveira Monteiro; Mariana Almeida; Luis Nogueira-Silva; Jorge Almeida
Journal:  Eur J Case Rep Intern Med       Date:  2021-03-05

3.  [Treatment of extreme anemia with polymerized bovine hemoglobin : Case report and review of the literature].

Authors:  A Meiser; H Knoll; T Meisel; M Schröder; T Volk
Journal:  Anaesthesist       Date:  2020-10-01       Impact factor: 1.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.